{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:05:06Z","timestamp":1790517906620,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Projects for \u201cMajor New Drugs Innovation and Development\u201d, China","award":["2018ZX09711003"],"award-info":[{"award-number":["2018ZX09711003"]}]},{"name":"National Science and Technology Major Projects for \u201cMajor New Drugs Innovation and Development\u201d, China","award":["2020JQ-232"],"award-info":[{"award-number":["2020JQ-232"]}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2018ZX09711003"],"award-info":[{"award-number":["2018ZX09711003"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2020JQ-232"],"award-info":[{"award-number":["2020JQ-232"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children. However, no specific antiviral drug is currently available for the treatment of this type of infection. The Unites States and United Kingdom health authorities recently approved a new antiviral drug, molnupiravir, for the treatment of COVID-19. In this study, we reported that molnupiravir (EIDD-2801) and its active form, EIDD-1931, have broad-spectrum anti-enterovirus potential. Our data showed that EIDD-1931 could significantly reduce the production of EV-A71 progeny virus and the expression of EV-A71 viral protein at non-cytotoxic concentrations. The results of the time-of-addition assay suggest that EIDD-1931 acts at the post-entry step, which is in accordance with its antiviral mechanism. The intraperitoneal administration of EIDD-1931 and EIDD-2801 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing the viral load in various tissues of the infected mice. The pharmacokinetics analysis indicated that the plasma drug concentration overwhelmed the EC50 for enteroviruses, suggesting the clinical potential of molnupiravir against enteroviruses. Thus, molnupiravir along with its active form, EIDD-1931, may be a promising drug candidate against enterovirus infections.<\/jats:p>","DOI":"10.3390\/v14061142","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T05:25:42Z","timestamp":1653974742000},"page":"1142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuexiang","family":"Li","sequence":"first","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzheng","family":"Yan","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Wang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"},{"name":"Institute of Medical Research, Northwestern Polytechnical University, Xi\u2019an 710072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Dai","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Yang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Guo","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Medical Research, Northwestern Polytechnical University, Xi\u2019an 710072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyuan","family":"Cao","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-620X","authenticated-orcid":false,"given":"Wu","family":"Zhong","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/01.inf.0000237798.07462.32","article-title":"Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983\u20132003","volume":"25","author":"Khetsuriani","year":"2006","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008\u20132012: An epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","unstructured":"Nichol, S.T., Beaty, B.J., Elliott, R.M., Goldbach, R., Plyusnin, A., Schmaljohn, C.S., and Tesh, R.B. (2005). Virus Taxonomy: Classification and Nomenclature of Viruses: 8th Report of the International Committee on Taxonomy of Viruses, Academic Press."},{"key":"ref_4","unstructured":"WPRO (2011). A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD), WHO Western Pacific Region."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2018.11.003","article-title":"Severe atypical hand-foot-and-mouth disease in adults due to coxsackievirus A6: Clinical presentation and phylogenesis of CV-A6 strains","volume":"110","author":"Broccolo","year":"2019","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/acsinfecdis.0c00120","article-title":"Enterovirus D68 Antivirals: Past, Present, and Future","volume":"6","author":"Hu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.RES.74.2.182","article-title":"Viral infection and the pathogenesis of dilated cardiomyopathy","volume":"74","author":"Martino","year":"1994","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cjca.2018.01.086","article-title":"Coxsackievirus B3-Induced Myocarditis: New Insights Into a Female Advantage","volume":"34","author":"Howlett","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/BOR.0b013e328353372d","article-title":"Update on coxsackievirus B3 myocarditis","volume":"24","author":"Fairweather","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3201\/eid2403.171303","article-title":"Epidemiology of Recurrent Hand, Foot and Mouth Disease, China, 2008\u20132015","volume":"24","author":"Huang","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","first-page":"999","article-title":"Epidemiological Characteristics of Hand, Foot, and Mouth Disease Outbreaks in Qingdao, 2009\u20132018","volume":"50","author":"Jia","year":"2021","journal-title":"Iran. J. Public Health"},{"key":"ref_12","first-page":"416","article-title":"Clinico-radiological spectrum in enterovirus 71 infection involving the central nervous system in children","volume":"21","author":"Lee","year":"2014","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Han, Z., Zhang, Y., Huang, K., Wang, J., Tian, H., Song, Y., Yang, Q., Yan, D., Zhu, S., and Yao, M. (2019). Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4107-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12985-021-01560-w","article-title":"Simultaneous enterovirus EV-D68 and CVA6 infections causing acute respiratory distress syndrome and hand, foot and mouth disease","volume":"18","author":"Giamberardino","year":"2021","journal-title":"Virol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/22221751.2021.1899772","article-title":"The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China","volume":"10","author":"Jiang","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00766","DOI":"10.1128\/AAC.00766-18","article-title":"Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2021.09.009","article-title":"Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses","volume":"564","author":"Wang","year":"2021","journal-title":"Virology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1743-422X-7-116","article-title":"Producing infectious enterovirus type 71 in a rapid strategy","volume":"7","author":"Han","year":"2010","journal-title":"Virol. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41467-017-00477-9","article-title":"Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody","volume":"8","author":"Xu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/21645515.2019.1565266","article-title":"A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge","volume":"15","author":"Du","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41564-018-0275-7","article-title":"Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization","volume":"4","author":"Zheng","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2010.08.080","article-title":"Combined peptides of human enterovirus 71 protect against virus infection in mice","volume":"28","author":"Liu","year":"2010","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, Z., Xu, L., He, D., Yang, L., Liu, C., Chen, Y., Shih, J.W., Zhang, J., Zhao, Q., and Cheng, T. (2014). In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PloS ONE, 9.","DOI":"10.1371\/journal.pone.0109391"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2019.04.048","article-title":"Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent","volume":"175","author":"Hao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cell.2015.10.046","article-title":"Defining Hsp70 Subnetworks in Dengue Virus Replication Reveals Key Vulnerability in Flavivirus Infection","volume":"163","author":"Taguwa","year":"2015","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2019-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1128\/JVI.01207-14","article-title":"Inhibition of enterovirus 71 by adenosine analog NITD008","volume":"88","author":"Deng","year":"2014","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2014.10.009","article-title":"An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation","volume":"112","author":"Shang","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/S0264-410X(02)00182-2","article-title":"Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate","volume":"20","author":"Lin","year":"2002","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lee, C.C., Hsieh, C.C., and Ko, W.C. (2021). Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics., 10.","DOI":"10.3390\/antibiotics10111294"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:39Z","timestamp":1760138319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["v14061142"],"URL":"https:\/\/doi.org\/10.3390\/v14061142","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}